The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism

Not Applicable

• Conditions: COPD Exacerbation; PTE - Pulmonary Thromboembolism
• Interventions: Drug: Warfarin

• Registration Number: NCT03185845
• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Brief Summary

Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The thromboembolism risk is especially high in patients with chronic obstructive pulmonary disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-06
• Study First Submitted: 2017-06-12
• Study First Submitted QC: 2017-06-12
• Last Update Submitted: 2017-06-12
• Study First Posted: 2017-06-14
• Last Update Posted: 2017-06-14
• Study Start: 2017-06-15
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 392

Inclusion Criteria

• Hospitalized patients due to chronic obstructive pulmonary disease exacerbation and diagnosed as newly developed pulmonary thromboembolism
• Regular anticoagulation for 3 months and got CT pulmonary angiography

Exclusion Criteria

• Patients with major bleeding during prior anticoagulation
• Patients need long term anticoagulation to treat other diseases
• Patients unwilling to receive prolonged anticoagulation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Prolonged anticoagulation	Warfarin	3 months longer anticoagulation after regular treatment

Primary Outcome Measures

Name	Time	Method
Venous thromboembolism recurrence	3 years	recurrence rate in %

Secondary Outcome Measures

Name	Time	Method
Chronic obstructive pulmonary disease exacerbations	3 year	total times

Trial Locations

Locations (1)

Beijing Chaoyang Hospital; 🇨🇳 Beijing, Beijing, China